Table 3.

PSP-related therapeutic implications

Compound	Target	Type of cancer	Activator/Inhibitor	Mechanism/Pathway	Comments	Ref.
Sephin1	PP1-GADD34	ATC	Inhibitor	-	Growth inhibition and chemical sensation	180
Raphin1	PP1-PP1R15B	Myeloma	Inhibitor	Activating EIF2α/ATF4/CHOP pathway	Apoptosis promotion and chemical sensation	181
FTY720/ fingolimod	PP2A- B56γ	Lymphoma, breast, pancreatic cancer	Activator	Disrupting PP2A-SET interaction	Growth inhibition in various tumor cells, immunosuppression	62
C11	PP2A- B56γ	CLL	Activator	Disrupting PP2A-SET interaction	Growth inhibition in CLL, analog to FTY720 without immunosuppression	169
CM-1231	PP2A- B56γ	AML	Activator	Disrupting PP2A-SET interaction	Growth inhibition in AML, analog to FTY720 without cardiac toxicity	170
DT-061 /SMAP	PP2A-B56α	CLL, lung cancer	Activator	Inhibiting MEK/mTOR and NOTCH1 pathway, mPTPs-mediated apoptosis	Growth inhibition in K-RAS mutant lung cancer, and CLL	172-174
LB-100	PP2A	Glioblastoma, CRC, lung cancer	Inhibitor	-	Success in phase I and phase II trials, chemo-/radio-sensitization	177
DMC	PP2A	CRC	Inhibitor	Activating PI3K/AKT/mTOR pathway	Immune TME modulation	150
SHAP	PP2A-STRN3	Gastric cancer	Inhibitor	Inhibiting HIPPO pathway	Growth inhibition	10
CSP	Calcineurin	CML	Inhibitor	Inhibiting Wnt/calcineurin/NFAT pathway	Chemo-sensitization, low tolerance	167
Zoledronic acid	Calcineurin	Various cancers with skeletal metastases	Inhibitor	Inhibiting NFAT and IL-2 pathways	Immune TME modulation	71
Rubiginosin B	Calcineurin	CRC	Inhibitor	Inhibiting NFAT pathway	Immune TME modulation	70
GSK2830371/ GlaxoSmithKline	PPM1D	Hematopoietic, breast cancer	Inhibitor	P53 restoration	Growth inhibition	32
CCT007093	PPM1D	Medulloblastoma, OC	Inhibitor	P53 restoration	Growth inhibition and induced lethality	178, 179